Sign in

Kent Dauten

Director at IRON MOUNTAIN
Board

About Kent P. Dauten

Independent director of Iron Mountain; age 69; 28 years of Board service as of April 18, 2025. Chairman of Keystone Capital (since 2017), previously Managing Director since founding the firm in 1994; former president of HIMSCORP, a records management company Iron Mountain acquired in 1997. Education: BA in Economics (Dartmouth) and MBA (Harvard). The Board affirms his independence under NYSE standards and notes all non-employee directors met attendance expectations in 2024 .

Past Roles

OrganizationRoleTenureCommittees/Impact
Keystone CapitalChairmanSince Sep 2017Private investment leadership/capital markets experience
Keystone CapitalManaging DirectorFeb 1994–Sep 2017Business management and capital allocation expertise
HIMSCORP, Inc.Former PresidentNot disclosed; IRM acquired HIMSCORP in 1997Deep records management industry knowledge; prior lead independent director of IRM

External Roles

CompanyRoleTenureNotes
Health Management Associates, Inc.DirectorNov 1988–Aug 2013Prior public board experience
Current public company boardsNone disclosed in IRM’s 2025 proxy nominee summary

Board Governance

  • Committee assignments and 2024 activity:
    • Audit Committee: Member; 4 meetings in 2024; Audit members deemed “audit committee financial experts” and financially literate .
    • Nominating & Governance Committee: Member; 5 meetings in 2024 .
    • Finance Committee: Member; 4 meetings in 2024 .
  • Independence and attendance: Board confirms all non-employee directors (including Dauten) are independent; each incumbent director attended at least 75% of Board and committee meetings in 2024 .
  • Board structure and leadership: Independent Chair; executive sessions at each Board and committee meeting; hedging and pledging of Company stock by directors prohibited .
  • Director overboarding policy: limit of four public company boards for non-executives; Dauten shows no current public company boards beyond IRM in proxy summary .

Fixed Compensation

Component2024 Amount (USD)Notes
Annual Board Cash Retainer$85,000Standard non-employee director retainer
Committee Member Retainers$45,000$15,000 each for Audit, Nominating & Governance, Finance
Total Cash Fees$130,000As reported for Dauten
Equity Grant (RSUs)$189,9412,385 RSUs granted May 30, 2024; vested immediately
2025 Change (Board retainer)$90,000Effective Jan 1, 2025
2025 Change (Annual RSU value)$220,000Effective Jan 1, 2025

Performance Compensation

  • Director equity is time-based (RSUs vest immediately); no performance-based components for directors disclosed .

Other Directorships & Interlocks

CategoryDetail
Prior public boardsHealth Management Associates, Inc. (1988–2013)
Compensation Committee interlocksNone reported by the company for 2024; Dauten is not listed as a Compensation Committee member

Expertise & Qualifications

  • Audit committee financial expert and financially literate (by Board determination) .
  • Capital markets and business management expertise (Keystone Capital) .
  • Deep records management industry knowledge (former HIMSCORP president; IRM acquisition in 1997) .
  • Extensive Board tenure and prior lead independent director experience at IRM .

Equity Ownership

HolderShares Beneficially OwnedOwnership %
Kent P. Dauten1,205,432Less than 1% of outstanding shares
  • Director stock ownership guidelines: must hold ≥6× annual cash retainer; all non-employee directors are in compliance as of April 18, 2025 .
  • Hedging and pledging: prohibited by policy; all directors in compliance with the Insider Trading Policy as of April 18, 2025 .

Governance Assessment

  • Strengths:
    • Multi-committee engagement (Audit, N&G, Finance) with formal risk, governance, and capital oversight responsibilities; Audit membership designates him as a financial expert .
    • Strong alignment: substantial beneficial ownership and compliance with strict director ownership guidelines; anti-hedging/anti-pledging policy in place .
    • Independence affirmed and attendance thresholds met in 2024; executive sessions at every meeting support independent oversight .
    • No related-party transactions requiring Audit Committee review in 2024, reducing conflict risk .
  • Watch items / potential red flags:
    • Very long tenure (28 years) can raise questions about perceived independence over time despite formal independence determinations .
    • Historical connection to HIMSCORP (acquired by IRM in 1997); while no current related-party exposure disclosed, prior ties warrant continued monitoring under the Related Persons Policy .